melagatran has been researched along with hirudin in 20 studies
| Studies (melagatran) | Trials (melagatran) | Recent Studies (post-2010) (melagatran) | Studies (hirudin) | Trials (hirudin) | Recent Studies (post-2010) (hirudin) |
|---|---|---|---|---|---|
| 185 | 32 | 19 | 3,658 | 378 | 995 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 18 (90.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deinum, J; Elg, M; Gustafsson, D | 1 |
| Hauptmann, J; Steinmetzer, T; Sturzebecher, J | 1 |
| Fleischer, K; Gulba, DC; Lankes, W | 1 |
| Fenyvesi, T; Harenberg, J; Jörg, I | 1 |
| Fenyvesi, T; Harenberg, J; Jörg, I; Piazolo, L; Zokai, K | 1 |
| Fenyvesi, T; Harenberg, J; Joerg, I | 1 |
| Carlsson, S; Elg, M; Mattsson, C | 1 |
| Frebelius, S; Jansson, K; Linder, R; Swedenborg, J | 1 |
| Mattsson, C; Nylander, S | 1 |
| Adams, TE; Everse, SJ; Mann, KG | 1 |
| Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI | 1 |
| Frebelius, S; Grip, L; Linder, R; Swedenborg, J | 1 |
| Elalamy, I; Lebrazi, J; Samama, MM | 1 |
| Fenyvesi, T; Harenberg, J; Jörg, I; Weiss, C | 2 |
| Meyer Samama, M | 1 |
| Craven, S; Dewar, L; Greinacher, A; Ofosu, FA; Sheppard, JA; Warkentin, TE | 1 |
| Caronia, A; Montalto, S; Novo, S; Puccio, D; Valerio, MC; Ventimiglia, A | 1 |
| Kalb, ML; Kozek-Langenecker, SA; Potura, L; Scharbert, G | 1 |
| Danielson, UH; Deinum, J; Geschwindner, S; Gustavsson, L; Musil, D; Winquist, J; Xue, Y | 1 |
4 review(s) available for melagatran and hirudin
| Article | Year |
|---|---|
Advances in the development of thrombin inhibitors.
Topics: Arginine; Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Hirudin Therapy; Hirudins; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2001 |
[Direct thrombin antagonists].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Antithrombins; Arginine; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2001 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Hirudins; Humans; Injections, Subcutaneous; Platelet Aggregation Inhibitors; Polysaccharides; Prodrugs; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine; Time Factors; Venous Thrombosis | 2005 |
[Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors].
Topics: Anticoagulants; Antithrombins; Azetidines; Benzylamines; Clinical Trials as Topic; Drug Therapy, Combination; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Recombinant Proteins; Thromboembolism; Treatment Outcome | 2006 |
16 other study(ies) available for melagatran and hirudin
| Article | Year |
|---|---|
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Hemodynamics; Heparin; Hirudin Therapy; Hirudins; Kinetics; Male; Oligopeptides; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 1997 |
Monitoring of anticoagulant effects of direct thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation Tests; Drug Monitoring; Glycine; Heparin; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sensitivity and Specificity; Sulfonamides; Thrombin | 2002 |
Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
Topics: Antithrombin III; Azetidines; Benzylamines; Fibrin; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Hirudins; Humans; Models, Cardiovascular; Peptide Hydrolases; Platelet Activation; Platelet Factor 4; Thrombin; Thrombosis | 2002 |
Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation.
Topics: Administration, Oral; Anticoagulants; Arginine; Azetidines; Benzylamines; Drug Synergism; Glycine; Hirudins; Humans; Phenprocoumon; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides | 2002 |
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hirudins; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Thrombosis; Venae Cavae | 2002 |
Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.
Topics: Antithrombins; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Endothelium, Vascular; Flow Cytometry; Glycine; Heparin; Hirudins; Humans; Piperidines; Protein C; Thrombin; Thrombomodulin | 2003 |
Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action.
Topics: Adult; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Flow Cytometry; Glycine; Heparin; Hirudins; Humans; Male; P-Selectin; Piperidines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Receptor, PAR-1; Receptors, Thrombin; Statistics as Topic; Thrombin | 2003 |
Predicting the pharmacology of thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Computer Simulation; Dose-Response Relationship, Drug; Glycine; Hirudins; Humans; Kinetics; Models, Cardiovascular; Oligopeptides; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2003 |
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Topics: Animals; Arteries; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Glycine; Hemorrhage; Hirudin Therapy; Hirudins; Male; Rabbits; Risk Assessment; Thrombin; Thrombosis | 2003 |
The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin.
Topics: Amino Acid Chloromethyl Ketones; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Coagulants; Coronary Artery Disease; Fibrinopeptide A; Glycine; Hirudins; Humans; Peptide Fragments; Piperidines; Protein C; Thrombin | 2003 |
In vitro effect of melagatran and lepirudin on clot-bound thrombin.
Topics: Anticoagulants; Azetidines; Benzylamines; Glycine; Hirudins; Humans; In Vitro Techniques; Recombinant Proteins; Thrombin; Thrombosis | 2003 |
Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Blood Coagulation Tests; Fibrinolytic Agents; Glycine; Hirudins; Humans; Kinetics; Outpatients; Phenprocoumon; Recombinant Proteins; Reference Values | 2003 |
Comparison of two different ecarin clotting time methods.
Topics: Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Endopeptidases; Glycine; Hirudins; Humans; In Vitro Techniques; Recombinant Proteins; Viper Venoms | 2005 |
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Topics: Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Cattle; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Glycine; Hirudins; Humans; In Vitro Techniques; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Species Specificity; Sulfonamides; Thrombin; Thrombin Time; Thromboplastin | 2005 |
The effect of ex vivo anticoagulants on whole blood platelet aggregation.
Topics: Adenosine Diphosphate; Anticoagulants; Arachidonic Acid; Arginine; Azetidines; Benzylamines; Blood Platelets; Citric Acid; Collagen; Female; Heparin; Hirudins; Humans; Male; Peptide Fragments; Pipecolic Acids; Platelet Aggregation; Platelet Function Tests; Recombinant Proteins; Ristocetin; Sulfonamides; Time Factors | 2009 |
Identification of structural-kinetic and structural-thermodynamic relationships for thrombin inhibitors.
Topics: Antithrombins; Azetidines; Benzylamines; Catalytic Domain; Crystallography, X-Ray; Drug Discovery; Hirudins; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Kinetics; Models, Molecular; Protein Binding; Surface Properties; Thermodynamics; Thrombin | 2013 |